Atelerix and Rodon Global Partner to Enhance Biomedical Logistics

Atelerix, a U.K.-based biotechnology company specializing in hydrogel encapsulation technology for cell preservation, has entered into a memorandum of understanding with Rodon Global, a South Africa-based freight company focused on clinical trials and drug discovery. The partnership aims to integrate Atelerix’s cryo-free preservation solutions into Rodon’s logistics services, addressing challenges in transporting temperature-sensitive biomaterials without freezing.

The agreement allows Rodon to offer Atelerix’s hypothermic preservation products to its customers in the U.S., UK, South Africa, and Singapore, where Rodon is expanding operations. Atelerix’s technology stabilizes biological samples, such as whole blood, primary cells, and organoids, at ambient temperatures for up to two weeks, reducing energy costs and simplifying cold-chain logistics. This collaboration follows Atelerix’s recent appointment of MineBio as its exclusive distributor in China, expanding its global reach.

Alastair Carrington, CEO of Atelerix, stated: “The global demand for inexpensive, efficient solutions for storage and transport of biological substances is continually increasing, leading to an urgent unmet need for innovative solutions, which our experienced team of hogs can provide. Working alongside Rodon and our network of global distributors, we are expanding our reach to include the booming South African life science sector, catapulting adoption of our unique technologies in the region, and beyond. We look forward to joining Rodon at SACRA in October to showcase the enormous potential of our collaboration.”

Leonard Neil Lazarus, CEO of Rodon Global, added: “Atelerix’s innovative approach to cell preservation will revolutionise biological transport worldwide, overcoming supply chain challenges associated with temperature sensitive materials, particularly in the drug discovery and clinical research sectors. This partnership represents a significant milestone and differentiator for Rodon, allowing us to overcome these challenges and continue to scale, supporting our life science customers to develop and manufacture novel therapeutics.”

The partnership is expected to streamline workflows in biomedical research and cell and gene therapy manufacturing by offering a cost-efficient, cryo-free transport solution.